Genomics and drug discovery services company Galapagos NV, has triggered another milestone payment in its alliance with Janssen Pharmaceutica NV in rheumatoid arthritis, receiving a milestone payment of €1.5 million. To date, Galapagos has earned more than €24 million in payments from Janssen under this alliance.
At the same time the Mechelen, Belgium-based company said it had received a €1 million milestone payment under its alliance with GlaxoSmithKline, in infectious diseases. Since initiation of this deal at the end of 2007, Galapagos has received a total of €6 million.
“Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in R&D revenues,” said Onno van de Stolpe, CEO of Galapagos.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
